about
14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2Biomarker validation: common data analysis concernsPartial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy.Ongoing provision of individual clinician performance data improves practice behavior.A pilot study evaluating predictors of postoperative outcomes after major abdominal surgery: Physiological capacity compared with the ASA physical status classification system.Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).How accurately can the peak skin dose in fluoroscopy be determined using indirect dose metrics?Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.Meta-analyses of colorectal cancer risk factors.Tumor uptake of hollow gold nanospheres after intravenous and intra-arterial injection: PET/CT study in a rabbit VX2 liver cancer model.Survival differences among women with de novo stage IV and relapsed breast cancer.Rabbit hepatic arterial anatomy variations: implications on experimental design.Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model.MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers.Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.Metrics of cellular and vascular infiltration of human acellular dermal matrix in ventral hernia repairsMetformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinomaCorrelating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods.Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial.Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma.Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancerRetrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstructionNeuromuscular monitoring and postoperative residual curarisation: a meta-analysis.Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinomaAn injectable nanoparticle generator enhances delivery of cancer therapeutics.Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.Bronchial artery embolization for the management of hemoptysis in oncology patients: utility and prognostic factors.A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin.Safety and diagnostic accuracy of percutaneous biopsy in upper tract urothelial carcinoma.Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma.Development of an Electroporation and Nanoparticle-based Therapeutic Platform for Bone Metastases.Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.Role of RPL39 in Metaplastic Breast Cancer.Two Decades of ICU Utilization and Hospital Outcomes in a Comprehensive Cancer Center.Efficacy of a Self-expanding Tract Sealant Device in the Reduction of Pneumothorax and Chest Tube Placement Rates After Percutaneous Lung Biopsy: A Matched Controlled Study Using Propensity Score Analysis.
P50
Q24318575-CCC411D2-AE71-44AE-89B8-30EB882C5571Q27024057-BA5532B0-9476-485E-9FDB-5FA0450A7650Q33378977-A1AAF42A-D4D2-4800-AB96-3EA8201D0B51Q33597347-A1A74FA3-C5B2-4118-8509-11F6AC791354Q33723573-C80E0E83-EDBF-4400-B293-1D439C9B74E3Q33813216-20820DFD-45AC-4D7D-9DA2-46CA87EA852CQ33929880-B16BCB9A-1FEC-4DDB-9188-FB059EFDC03AQ33947907-9DBDBB80-B7A3-449B-85B8-3DA48BDDFBA5Q34165563-90227283-6728-495C-ACDB-6496060F2DE4Q34185914-E21C3089-0217-456B-B434-5634B6E5AD5FQ34231099-0D3BA19C-151C-4642-A231-066B1CAD9F46Q34672595-782E4528-DA4D-48F4-A4BD-E5A1F8E6CE8CQ34722614-6AC65377-32D6-4B20-B5BC-16894777F644Q34802292-87FEDDE7-853B-4A8D-8236-421EE3C8D53AQ35170258-9B1862B1-CFD2-46A3-B60D-B009EAA9EC7FQ35861564-FED1B96A-F617-48C1-AAD1-5ECC9B6FB29FQ36070998-A0D77A84-0C59-4238-BFA2-E600488594F4Q36109481-16F42CC0-4C5A-4F21-B52D-C27F192B3F7AQ36115834-B2B1F5D1-5726-489D-8584-884D0BE0A0DFQ36254925-13BE6E11-FF24-47A2-9B4A-621C358B842BQ36286689-71C144CE-8AA3-48F4-8500-8658907A759FQ36508067-10D051C2-467C-4D9D-A8A1-6FA25D4EDB07Q36528359-C668A88D-ED11-4FF6-ADE3-C25E795E1E7EQ36739081-18BEC0C5-DCFC-4B5E-907D-3B9C6CE96AA5Q36779798-7D6AE875-4EB9-4079-B0D7-08FE4D018424Q36893137-ACDAB6D5-BB20-4355-B903-012A9245656AQ37165239-EA7642A5-157C-4115-AF7C-F5D54A38231CQ37197236-319DE47F-914D-4C82-815D-8479B85DBAC8Q37351049-8F737C7F-C750-4C8B-B13C-C53EA6E904C6Q37429963-AA4A1DA2-6636-4E33-8B27-12806BCA89DDQ37465786-C6752D01-6765-4D10-836B-61D45BC48910Q37483253-6873D01E-16FD-4210-8781-FF841B10E5B3Q37687191-8043B0A6-8F85-491F-970F-846229DAC2ACQ38218248-F616EFD7-4E58-472E-975B-D700977A668DQ38433858-1DEE59C6-9969-4A5D-A8A6-038D59ACEE56Q38616198-05703570-F6E8-4D9A-A70D-4445CF901842Q38669236-853D1C90-EE10-4B7E-8173-372F5F105920Q38723382-F812E87B-B2C4-4A33-B8F1-F33211F54F93Q38920970-531EBF8D-3954-49AE-B2C7-05FEFEBE4044Q39202843-68F8B59C-A47B-48B4-9C7C-1E5E404018B5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joe E. Ensor
@ast
Joe E. Ensor
@en
Joe E. Ensor
@es
Joe E. Ensor
@nl
Joe E. Ensor
@sl
type
label
Joe E. Ensor
@ast
Joe E. Ensor
@en
Joe E. Ensor
@es
Joe E. Ensor
@nl
Joe E. Ensor
@sl
prefLabel
Joe E. Ensor
@ast
Joe E. Ensor
@en
Joe E. Ensor
@es
Joe E. Ensor
@nl
Joe E. Ensor
@sl
P106
P1153
12754105300
P21
P31
P496
0000-0003-3533-4388